Journal Mobile Options
Table of Contents
Vol. 16, No. 1, 2008
Issue release date: December 2007
Section title: Paper
Free Access
Neurosignals 2008;16:19–23
(DOI:10.1159/000109755)

PENN Biomarker Core of the Alzheimer’s Disease Neuroimaging Initiative

Shaw L.M.
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pa., USA
email Corresponding Author

Leslie M. Shaw, PhD

Department of Pathology and Laboratory Medicine

7 Founders Pavilion, 3400 Spruce Street

Philadelphia, PA 19104 (USA)

Tel. +1 215 662 6575, Fax +1 215 662 7529, E-Mail shawlmj@mail.med.upenn.edu


References

  1. Heberty LE, Scherr PA, Bienias JL, et al: Alzheimer disease in the US population. Arch Neurol 2003;1119–1122.
    External Resources
  2. Alzheimer’s Association: Fact Sheet, Alzheimer’s Disease. www.alz.org.
  3. Forman MS, Trojanowski JQ, Lee VM-Y: Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004;10:1055–1063.
  4. Selkoe DJ: Cell biology of protein misfolding: the examples of Alzheimer’s and Parkinson’s diseases. Nat Cell Biol 2004;6:1054–1061.
  5. Skovronsky DM, Lee VM-Y, Trojanowski JQ: Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol Mech Dis 2006;1:151–170.
  6. Forman MS, Farmer J, Johnson JK, et al: Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006;59:952–962.
  7. Forman MS, Lee VM-Y, Trojanowski JQ: Nosology of Parkinson’s disease: looking for the way out of a quackmire. Neuron 2005;47:479–482.
  8. Savitt JM, Dawson VL, Dawson TM: Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006;116:1744–1754.
  9. McKeith IG, Dickson DW, Lowe J, et al: Dementia with Lewy bodies: diagnosis and management: third report of the DLB Consortium. Neurology 2005;65:1863–1872.
  10. Shaw LM, Korecka M, Clark CM, Lee VM-Y, Trojanowski JQ: Biomarkers of neurodegeneration for diagnosing and monitoring therapeutics. Nat Rev Drug Discov 2007;6:295–303.
  11. Blennow K, Hampel H: CSF markers for incipient Alzheimer’s disease. Lancet Neurol 2003;2:605–613.
  12. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, et al: Decreased β-amyloid1–42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094–2103.
  13. Hannson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–234.
  14. Consensus report of the Working Group on: ‘Biological Markers of Alzheimer’s Disease’. The Ronald and Nancy Reagen Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging 1998;19:109–116.
  15. Frank RA, Galasko D, Hampel H, Hardy J, de Leon MJ, et al: Biological markers for therapeutic trials in Alzheimer’s disease – proceedings of the Biological Measures Working Group: NIA Initiative on Neuroimaging in Alzheimer’s Disease. Neurobiol Aging 2003;24:521–536.
  16. Thal LJ, Kantarci K, Reiman EM, et al: The role of biomarkers in clinical trials for Alzheimer’s disease. Alzheimer Dis Assoc Disord 2006;20:6–15.
  17. Clarke R, Smith D, Jobst DM, Refsum H: Folate, vitamin B12 and serum homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55:1449–1455.
  18. Seshadri S, Beiser A, Selhub J, et al: Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002;346:476–483.
  19. Hsiung G-YR, Sadovnick AD, Feldman H: Apolipoprotein E ε4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging. Can Med Assoc 2004;171:863–867.
  20. Dubois R, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, et al: Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734–746.